|

The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study

RECRUITINGSponsored by Yonsei University
Actively Recruiting
SponsorYonsei University
Started2014-05
Est. completion2029-02
Eligibility
Age19 Years+
Healthy vol.Accepted

Summary

1\. Purpose of the study 1\) To explore clinical recurrence associated clinical factors including age, sex, clinical, electrophysiological, anatomical, imaging, and serologic characteristics. 2\) To develop simulation model to predict clinical recurrence and the efficacy of catheter ablation 2. Scientific evidence of the study 1. In atrial fibrillation patients, the maintenance of normal sinus rhythm showed significant reduction of mortality. 2. drug therapy with anti-arrhythmic drug showed many complications and side effect, thus non-drug therapy such as catheter ablation is developed. 3. catheter ablation has been performed for 10years world-wide, and showed superior treatment outcome compared with drug therapy. 4. clinical outcome after catheter ablation is affected not only by age, sex and underlying disease, but also by electrophysiologic, imaging, serologic and electroanatomical remodeling of the heart. However, there are few studies concerning these multifactorial variables. 3\. Study population

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation

Exclusion Criteria:

* patients who do not agree with study inclusion
* permanent AF refractory to electrical cardioversion
* AF with valvular disease ≥ grade 2
* patients with left atrial diameter greater than 60mm
* patients with age less than 19

Conditions2

Atrial FibrillationHeart Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.